Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Com Stk Usd0.01 [Di] (MXCT.LN)

Com Stk Usd0.01 [Di] (MXCT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 170,110
  • Shares Outstanding, K 106,319
  • Annual Sales, $ 38,627 K
  • Annual Income, $ -41,055 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 6.06
  • Price/Cash Flow N/A
  • Price/Book 1.16
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings $-0.10 on 05/08/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
147.692 +2.92%
on 06/25/25
172.000 -11.63%
on 06/10/25
-9.150 (-5.68%)
since 05/23/25
3-Month
147.692 +2.92%
on 06/25/25
241.000 -36.93%
on 03/26/25
-88.000 (-36.67%)
since 03/25/25
52-Week
147.692 +2.92%
on 06/25/25
407.840 -62.73%
on 01/21/25
-176.000 (-53.66%)
since 06/25/24
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
MaxCyte Announces Planned CFO Transition in 2026 GlobeNewswire - Wed Nov 12, 3:08PM CST

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance GlobeNewswire - Wed Nov 12, 3:05PM CST

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 GlobeNewswire - Wed Oct 8, 7:05AM CDT

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors GlobeNewswire - Mon Oct 6, 7:05AM CDT

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability GlobeNewswire - Mon Sep 22, 3:30PM CDT

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance GlobeNewswire - Wed Aug 6, 3:05PM CDT

ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Signs Platform License Agreement with Adicet Bio GlobeNewswire - Mon Aug 4, 7:05AM CDT

MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE)...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline GlobeNewswire - Thu Jul 31, 7:05AM CDT

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc ., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 GlobeNewswire - Wed Jul 9, 7:05AM CDT

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies GlobeNewswire - Wed Jun 11, 1:00AM CDT

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.5200 (-5.00%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 171.077
2nd Resistance Point 165.539
1st Resistance Point 158.769
Last Price 152.000
1st Support Level 146.461
2nd Support Level 140.923
3rd Support Level 134.153

See More

52-Week High 407.840
Fibonacci 61.8% 308.463
Fibonacci 50% 277.766
Fibonacci 38.2% 247.069
Last Price 152.000
52-Week Low 147.692

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot